Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial

被引：15
|
作者：
Shang, X. [1 ]
Zhang, C. [1 ]
Zhao, G. [2 ]
Zhang, W. [3 ]
Liu, L. [3 ]
Duan, X. [1 ]
Yue, J. [1 ]
Ma, Z. [1 ]
Chen, C. [1 ]
Meng, B. [2 ]
Ren, X. [3 ]
Jiang, H. [1 ]
机构：
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Minimally Invas Esophageal Surg, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页码：S1428 / S1429
页数：2
相关论文
共 50 条
  • [31] Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research
    Wang, X.
    Ma, J.
    Zhang, J.
    Yang, Y.
    Zheng, D.
    Liang, H.
    Zhang, L.
    Xin, Y.
    Ling, X.
    Fang, C.
    Jiang, H.
    Zheng, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1400 - S1400
  • [32] CAMRELIZUMAB COMBINED WITH PACLITAXEL AND NEDAPLATIN IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM, EXPLORATORY RESEARCH
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A437 - A437
  • [33] Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study
    Xia, Pinghui
    Li, Pan
    Wu, Simeng
    Wang, Yiqing
    Ye, Peng
    Zhang, Chong
    Hu, Jian
    Kidane, Biniam
    Lampridis, Savvas
    Velotta, Jeffrey B.
    Wakefield, Connor J.
    Zhu, Linhai
    Wang, Luming
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [34] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [35] Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial
    Liu, T.
    Xiao, D.
    Li, Q.
    Chen, Y.
    Tian, J.
    Lin, Z.
    Ding, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S35 - S35
  • [36] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
  • [37] Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study
    Qu, Yanli
    Munire, Abulimiti
    Zhou, Ning
    Saifuding, Keyoumu
    Bulibu, Jilisihan
    Wang, Wei
    Tang, Xushan
    Li, Na
    Li, Junjie
    Wang, Peihong
    Tang, Yong
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 1 - 11
  • [38] Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study
    Zhao, Jinbo
    Yan, Xiaolong
    Bai, Yuquan
    Duan, Hongtao
    Jiang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase., single-arm, exploratory research.
    Ma, Jianqun
    Zhang, Jinfeng
    Yang, Yingnan
    Zheng, Dayong
    Wang, Xiaoyuan
    Liang, Hao
    Zhang, Luquan
    Xin, Yanzhong
    Ling, Xiaodong
    Fang, Chengyuan
    Jiang, Hao
    Zheng, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC): A single-center, single-arm, exploratory clinical trial
    Yang, Ji Chen
    Jiao, Wenjie
    Hua, Feng
    Zhao, Xiaoming
    Yang, Wenfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345